Originally published as JCO Early Release 10.1200/JCO.2003.01.238 on September 8 2003
Journal of Clinical Oncology, Vol 21, Issue 20
(October), 2003: 3761-3769
© 2003 American Society for Clinical Oncology
Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors
Matthew P. Goetz,
Charles Erlichman,
Anthony J. Windebank,
Joel M. Reid,
Jeffrey A. Sloan,
Pamela Atherton,
Alex A. Adjei,
Joseph Rubin,
Henry Pitot,
Evanthia Galanis,
Matthew M. Ames,
Richard M. Goldberg
From the Division of Medical Oncology, Division of Oncology Research, Biostatistics, and Department of Neurology, Mayo Clinic, Rochester, MN.
Address reprint requests to Matthew P. Goetz, MD, Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: goetz.matthew{at}mayo.edu.
Purpose: We sought to determine the maximum-tolerated dose (MTD) and evaluate the toxicities and clinical activity of two irinotecan (CPT-11), fluorouracil (FU), leucovorin (LV), and oxaliplatin schedules in patients with advanced solid tumors. Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics.
Patients and Methods: Thirteen patients (cohort 1) received intravenous CPT-11 (infusion) and FU/LV (bolus) on days 1, 8, 15, and 22 and oxaliplatin (infusion) on days 1 and 15 every 6 weeks for a total 37 courses (median, three courses) at three dose levels. Twenty-two cohort 2 patients received intravenous CPT-11/oxaliplatin (infusion, day 1) and FU/LV (90-minute bolus infusion, days 2 to 5) every 3 weeks for a total of 122 courses (median, four courses) at three dose levels. Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD.
Results: Dose-limiting toxicity (DLT) seen in both cohorts at the starting dose required dose de-escalation. Cohort 1 DLT included diarrhea and neutropenia. In cohort 2, diarrhea, vomiting, dehydration, neutropenia, febrile neutropenia, and paresthesias were DLTs. Antitumor activity was seen in both cohorts. In cohort 2, the total platinum area under the curve of patients increased 17% in cycle 2 (P = .048), but objective neurotoxicity was not seen.
Conclusion: The toxicities resulting from the addition of oxaliplatin to CPT-11/FU/LV are significant but manageable. The MTDs for the weekly schedule are CPT-11 (75 mg/m2), oxaliplatin (50 mg/m2), FU (320 mg/m2), and LV (20 mg/m2); and, for the 3-weekly schedule, the MTDs are CPT-11 (175 mg/m2), oxaliplatin (85 mg/m2), FU (240 mg/m2), and LV (20 mg/m2). Second-cycle platinum accumulation raises the possibility for enhanced cumulative neurotoxicity with CPT-11/oxaliplatin combinations.
Supported in part by grant Nos. CA15083 and CA69912 and grant No. M01 RR00585 from the Mayo Clinic General Clinical Research Center, Rochester, MN.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al.
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
J. Clin. Oncol.,
May 1, 2007;
25(13):
1670 - 1676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc.,
January 1, 2007;
82(1):
114 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, I. Brunetti, E. Fontana, S. Ricci, M. Andreuccetti, and A. Falcone
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
Ann. Onc.,
December 1, 2004;
15(12):
1766 - 1772.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. A. Punt
New options and old dilemmas in the treatment of patients with advanced colorectal cancer
Ann. Onc.,
October 1, 2004;
15(10):
1453 - 1459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Rothenberg and J. D. Berlin
Therapeutic Strategies for Metastatic Colorectal Cancer: Simultaneous, Sequential, or Specific?
J. Clin. Oncol.,
October 15, 2003;
21(20):
3716 - 3717.
[Full Text]
[PDF]
|
 |
|
|